# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Acute myeloid leukemia

Acute Non Lymphoblastic Leukemia
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 41-50 of 671 results.
A Phase I/IIa Clinical Research of TJ011133 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (r/r AML)
Status: Not yet recruiting
Last Changed: Mar 26, 2020
First Received: Dec 17, 2019
Disease(s): Acute Myeloid Leukemia
Intervention(s): TJ011133
Triple Combination of Pevonedistat and Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Status: Not yet recruiting
Last Changed: Mar 25, 2020
First Received: Feb 12, 2020
Disease(s): Acute Myeloid Leukemia
Intervention(s): Pevonedistat, Venetoclax, Azacitidine
Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)
Status: Recruiting
Last Changed: Sep 13, 2019
First Received: Jun 26, 2018
Disease(s): Acute Myeloid Leukemia
Intervention(s): Atovaquone, Cytarabine, Daunorubicin, Etoposide, Gemtuzumab Ozogamicin
Locations: Johns Hopkins Medicine, Baltimore, Maryland, United States
Baylor College of Medicine, Houston, Texas, United States
Seattle Children's Hospital, Seattle, Washington, United States
GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia
Status: Recruiting
Last Changed: Jan 21, 2020
First Received: Aug 09, 2019
Disease(s): ACUTE MYELOID LEUKEMIA
Intervention(s): Glasdegib, Decitabine
Locations: Yale Cancer Center/Smilow, New Haven, Connecticut, United States
Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)
Status: Recruiting
Last Changed: Mar 26, 2020
First Received: Jun 11, 2018
Disease(s): Acute Myeloid Leukemia
Intervention(s): Quizartinib, Milademetan, Milademetan
Locations: Ronald Reagan Medical Center, UCLA, Los Angeles, California, United States
Yale Cancer Center, New Haven, Connecticut, United States
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
University of Kansas Cancer Center, Fairway, Kansas, United States
Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, United States
... and 6 other locations.
Study Impact on Outcome of Eltrombopag in Elderly Patients With Acute Myeloid Leukemia Receiving Induction Chemotherapy
Status: Recruiting
Last Changed: Oct 24, 2018
First Received: Jul 27, 2018
Disease(s): Acute Myeloid Leukemia
Intervention(s): Eltrombopag, Placebo
Locations: CHU ANGERS - Maladies du sang, Angers, France
CH de la Côte Basque - Hématologie, Bayonne, France
CHU Estaing, Clermont-Ferrand, France
CHU Grenoble - Hématologie Clinique, Grenoble, France
Institut Paoli-Calmettes - Hématologie 2, Marseille, France
... and 11 other locations.
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
Status: Recruiting
Last Changed: Nov 13, 2019
First Received: Aug 28, 2019
Disease(s): Acute Myeloid Leukemia
Intervention(s): Gemtuzumab Ozogamicin, Venetoclax
Locations: Univeristy of Illinois, Chicago, Illinois, United States
Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia
Status: Recruiting
Last Changed: Feb 13, 2020
First Received: Dec 15, 2017
Disease(s): Acute Myeloid Leukemia
Intervention(s): Gemtuzumab Ozogamicin (GO), Donor Leukocytes
Locations: Rhode Island Hospital, Providence, Rhode Island, United States
Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia
Status: Recruiting
Last Changed: Dec 12, 2019
First Received: Jan 20, 2017
Disease(s): Acute Myeloid Leukemia
Intervention(s): DNT cells
Locations: Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Status: Recruiting
Last Changed: Mar 26, 2020
First Received: Oct 10, 2018
Disease(s): Acute Myeloid Leukemia
Intervention(s): Cytarabine, Daunorubicin, Uproleselan
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Community Cancer Institute, Clovis, California, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
Loma Linda University Medical Center, Loma Linda, California, United States
Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
... and 163 other locations.